首页> 外文OA文献 >Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status

【2h】

Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status

机译：Pembrolizumab作为顺铂型尿液癌（Keynote-052）中的一线治疗：老年患者的结果按年龄和性能状况

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Petros Grivas; Elizabeth R. Plimack; Arjun V. Balar; Daniel Castellano; Peter H. O’Donnell; Joaquim Bellmunt; Thomas Powles; Noah M. Hahn; Ronald de Wit; Dean F. Bajorin; Misoo C. Ellison; Tara L. Frenkl; James L. Godwin; Jacqueline Vuky;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J] . Balar Arjun V., Castellano Daniel, ODonnell Peter H., The lancet oncology . 2017,第11期

机译：第一线Pembrolizumab在顺铂 - 不合格患者患有局部晚期和不可切除或转移性尿路上皮癌症（Keynote-052）：多期，单臂，第2期研究
2. First-line pembrolizumab therapy in a cisplatin-ineligible patient with plasmacytoid urothelial carcinoma: A case report [J] . Hunter Lindsay, Moser Justin, Sturge Caleb, Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners . 2020,第1期

机译：第一线彭尔洛丽盛疗法在双铂型尿液尿路上皮癌的顺铂 - 不合别患者：案例报告
3. PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients - Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer [J] . Irene Resch, Shahrokh F. Shariat, Kilian M. Gust Memo - Magazine of European medical oncology . 2018,第1期

机译：PD-1和PD-L1抑制剂在铂金疗法中或在顺铂型患者中的一线治疗后 - 急剧提高预后和转移性尿路上皮癌患者无望的数十年后的预后和整体生存
4. Clinical Outcome of Breast and Ovarian Cancer Patients Treated after High-Dose Chemotherapy and Autologous Stem Cell Rescue with Theratope (STn-KLH) Cancer Vaccine: Theratope (STn-KLH) Cancer Vaccine following Autologous Transplant [C] . Leona A. Holmberg, Katherine A. Guthrie, Brenda M. Sandmaier Chemical glycobiology . -1

机译：大剂量化学疗法和自体干细胞拯救治疗的Theratope（STn-KLH）癌症疫苗治疗的乳腺癌和卵巢癌患者的临床结果：自体移植后的Theratope（STn-KLH）癌症疫苗
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Atezolizumab as first-line therapy in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm multicentre phase 2 trial [O] . Arjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, -1

机译：Atezolizumab作为不适合顺铂治疗的局部晚期和转移性尿路上皮癌患者的一线治疗：一项单臂多中心2期试验
7. Phase III LEAP-011 trial: First-line pembrolizumab with lenvatinib in patients with advanced urothelial carcinoma ineligible to receive platinum-based chemotherapy [O] . Y. Loriot, A. Balar, R. de Wit, 2019

机译：III阶段Leap-011试验：一线Pembrolizumab与Lenvatinib患者患者，尿路上皮癌的患者有不合格接受基于铂的化疗

Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status

著录项

引文网络

相似文献

相关主题

期刊订阅